Updates

Ergomed - Well set for an eps ‘beat’

August 2022

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The change at Ergomed over the past three years is seismic: compared to £2.5m ebitda in 2018, this year’s forecast is £28.5m and even this is seemingly too light.Ahead of reporting around 26 September, this month’s H1 update reported sales up an impressive 25% to just shy of £70m. Including 3.5m months from ADAMAS (whose activities straddle the group's two divisions), the drug safety monitoring (or pharmacovigilance) division grew sales 23% to £35.6m and the Contract Research Organisation (CRO) side grew sales by 26% to £34.3m.PV remains a solid annuity type income at high gross margin whilst seven months into the year CRO has achieved close to 100% of the work to hit H2. With no earnouts payable ADAMAS has already integra ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

T Clarke

XLMedia

Ergomed - Permira bids 1350p (September 2023)

Ergomed - 80%+ of this year’s forecast covered (September 2022)

Ergomed (April 2022)

Ergomed - Buys specialist consultancy for £25.6m (March 2022)

Ergomed (October 2021)

Ergomed (May 2021)

Ergomed (January 2021)

Ergomed - "Hidden order bank" (October 2020)

Ergomed - Another big "beat" (August 2020)

Ergomed - Forecasts lifted again - by 5% (July 2020)

Ergomed - COVID-19 trial work underway (April 2020)

Ergomed - Earnings accretive deal (February 2020)

Ergomed - Taking a share in a winning streak (October 2019)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X